

Attorney Docket No.: 3469.224-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Rasmussen et al.

Application No.: 09/189,028

Group Art Unit: 1652

Filed: November 10, 1998

Examiner: L. Hobbs

For: A Cellulase Preparation Comprising An Endoglucanase Enzyme

AMENDMENT AND PETITION TO CORRECT
INVENTORSHIP UNDER 37 C.F.R. §1.48(b)Commissioner for Patents
Washington, DC 20231

Sir:

Please amend the above-captioned application as follows:

IN THE INVENTORSHIP

Please delete Grethe Rasmussen, Jan Møller Mikkelsen, Martin Schüleln and Shamkant Patkar as inventors.

REMARKS

This petition is filed under 37 C.F.R. §1.48(b) in support of Applicant's correction of the inventorship of the above-captioned application.

The correct inventors were named in the application when filed. However, as a result of prosecution of the application, only Fred Hagen, Carsten Malland Hjort, Sven Hastrup are inventors of the subject matter now claimed.

Applicants acknowledge that the invention of Grethe Rasmussen, Jan Møller Mikkelsen, Martin Schüleln and Shamkant Patkar is no longer being claimed in the application.

For the foregoing reasons, Applicants request that this petition be granted.

04/03/2002 TSUGGS

00000001 09/189,028

01 FC:122

1300000000


*use for
PA. 2nd only*

*#73
Dyplme
Fate
1.846*

Please charge the required fee (currently \$130.00) to our Deposit Account No. 14-1447. A duplicate of this paper is enclosed.

Respectfully submitted,

Date: October 25, 2000


Reza Green, Reg. No. 38,475
Novo Nordisk of North America, Inc.
405 Lexington Avenue, Suite 6400
New York, NY 10174-6401
(212) 867-0123

Complete and mail this form, together

) fees, to:

Box ISSUE FEE

Assistant Commissioner for Patent
Washington, D.C. 20231

MAILING INSTRUCTIONS: This form should be used for transmitting the ISSUE FEE, Blocks 1 through 4 should be completed where appropriate. All further correspondence including the Issue Fee Receipt, the Patent, advance orders and notification of maintenance fees will be mailed to the current correspondence address as indicated unless corrected below or directed otherwise in Block 1, by (a) specifying a new correspondence address; and/or (b) indicating a separate "FEE ADDRESS" for maintenance fee notifications.

CURRENT CORRESPONDENCE ADDRESS (Note: Legibly mark-up with any corrections or use Block 1)

HM12/0801

STEVE T ZELSON
NOVO NORDISK OF NORTH AMERICA INC
405 LEXINGTON AVENUE
SUITE 6200
NEW YORK NY 10017

Note: The certificate of mailing below can only be used for domestic mailings of the Issue Fee Transmittal. This certificate cannot be used for any other accompanying papers. Each additional paper, such as an assignment or formal drawing, must have its own certificate of mailing.

Certificate of Mailing

I hereby certify that this Issue Fee Transmittal is being deposited with the United States Postal Service with sufficient postage for first class mail in an envelope addressed to the Box Issue Fee address above on the date indicated below.

Carol McFarlane (Depositor's name)
Carol McFarlane (Signature)
October 31, 2000 (Date)

APPLICATION NO.	FILING DATE	TOTAL CLAIMS	EXAMINER AND GROUP ART UNIT	DATE MAILED
09/100,020	11/10/98	021	HOBBS, I	1652 08/01/00
First Named Applicant				

TITLE OF INVENTION

CELLULOSE PREPARATION COMPRISING AN ENDOGLUCANASE ENZYME

ATTY'S DOCKET NO.	CLASS-SUBCLASS	BATCH NO.	APPLN. TYPE	SMALL ENTITY	FEE DUE	DATE DUE
145, 224 US	435 200, 000	015	UTILITY	NO	1240.00 \$1240.00	11/01/00

1. Change of correspondence address or indication of "Fee Address" (37 CFR 1.363). Use of PTO form(s) and Customer Number are recommended, but not required.

☐ Change of correspondence address (or Change of Correspondence Address form PTO/SB/122) attached.

☐ "Fee Address" indication (or "Fee Address" indication form PTO/SB/47) attached.

2. For printing on the patent front page, list (1) the names of up to 3 registered patent attorneys or agents OR, alternatively, (2) the name of a single firm (having as a member a registered attorney or agent) and the names of up to 2 registered patent attorneys or agents. If no name is listed, no name will be printed.

1 Elias J. Lambiris, Esq.
2 Reza Green, Esq.
3 _____

3. ASSIGNEE NAME AND RESIDENCE DATA TO BE PRINTED ON THE PATENT (print or type)
PLEASE NOTE: Unless an assignee is identified below, no assignee data will appear on the patent. Inclusion of assignee data is only appropriate when an assignment has been previously submitted to the PTO or is being submitted under separate cover. Completion of this form is NOT a substitute for filing an assignment.

(A) NAME OF ASSIGNEE Novo Nordisk A/S(B) RESIDENCE: (CITY & STATE OR COUNTRY) Bagsvaerd, Denmark

Please check the appropriate assignee category indicated below (will not be printed on the patent)

☐ Individual ☒ corporation or other private group entity ☐ government

4a. The following fees are enclosed (make check payable to Commissioner of Patents and Trademarks):

☐ Issue Fee☐ Advance Order - # of Copies _____

4b. The following fees or deficiency in these fees should be charged to:

DEPOSIT ACCOUNT NUMBER 14-1447

(ENCLOSE AN EXTRA COPY OF THIS FORM)

☒ Issue Fee☒ Advance Order - # of Copies (2) two

The COMMISSIONER OF PATENTS AND TRADEMARKS IS requested to apply the Issue Fee to the application identified above.

(Authorized Signature)

(Date)

NOTE: The Issue Fee will not be accepted from anyone other than the applicant, a registered attorney or agent, or the assignee or other party in interest as shown by the records of the Patent and Trademark Office.

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending on the needs of the individual case. Any comments on the amount of time required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND FEES AND THIS FORM TO: Box Issue Fee, Assistant Commissioner for Patents, Washington D.C. 20231

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMIT THIS FORM WITH FEE

Complete and mail this form, together with appropriate fees, to: **Box ISSUE FEE**
Assistant Commissioner for Patent
Washington, D.C. 20231

MAILING INSTRUCTIONS: This form should be used for transmitting the ISSUE FEE. Blocks 1 through 4 should be completed where appropriate. All further correspondence including the Issue Fee Receipt, the Patent, advance orders and notification of maintenance fees will be mailed to the current correspondence address as indicated unless corrected below or directed otherwise in Block 1, by (a) specifying a new correspondence address; and/or (b) indicating a separate "FEE ADDRESS" for maintenance fee notifications.

CURRENT CORRESPONDENCE ADDRESS (Note: Legibly mark-up with any corrections or use Block 1)

HM12/0801

STEVE T ZELSON
 NOVO NORDISK OF NORTH AMERICA INC
 405 LEXINGTON AVENUE
 SUITE 6200
 NEW YORK NY 10017

Note: The certificate of mailing below can only be used for domestic mailings of the Issue Fee Transmittal. This certificate cannot be used for any other accompanying papers. Each additional paper, such as an assignment or formal drawing, must have its own certificate of mailing.

Certificate of Mailing

I hereby certify that this Issue Fee Transmittal is being deposited with the United States Postal Service with sufficient postage for first class mail in an envelope addressed to the Box Issue Fee address above on the date indicated below.

Carol McFarlane (Depositor's name)

Carol McFarlane (Signature)

October 31, 2000 (Date)

APPLICATION NO.	FILING DATE	TOTAL CLAIMS	EXAMINER AND GROUP ART UNIT	DATE MAILED
09/189,020	11/10/98	021	HOBBS, I	1652 09/01/00
First Named Applicant	RASMUSSEN, 35 USC 154(b) term ext. 0 Days			

TITLE OF INVENTION
 CELLULOSE PREPARATION COMPRISING AN ENDOGLUCANASE ENZYME

ATTY'S DOCKET NO.	CLASS-SUBCLASS	BATCH NO.	APPLN. TYPE	SMALL ENTITY	FEE DUE	DATE DUE
3459-224-US	405-200,000	015	UTILITY	NO	1240.00	11/01/00
0470	0470	0470	0470	0470	0470	0470

1. Change of correspondence address or indication of "Fee Address" (37 CFR 1.363). Use of PTO form(s) and Customer Number are recommended, but not required.

☐ Change of correspondence address (or Change of Correspondence Address form PTO/SB/122) attached.

☐ "Fee Address" indication (or "Fee Address" indication form PTO/SB/47) attached.

2. For printing on the patent (front page, list (1) the names of up to 3 registered patent attorneys or agents OR, alternatively, (2) the name of a single firm (having as a member a registered attorney or agent) and the names of up to 2 registered patent attorneys or agents. If no name is listed, no name will be printed.

1. Elias J. Lambiris, Esq.
 2. Reza Green, Esq.

3. ASSIGNEE NAME AND RESIDENCE DATA TO BE PRINTED ON THE PATENT (print or type)
PLEASE NOTE: Unless an assignee is identified below, no assignee data will appear on the patent. Assignment of assignee data is only appropriate upon assignment has been previously submitted to the PTO or is being submitted under separate cover. Completion of this form is NOT a substitute for filing an assignment.

(A) NAME OF ASSIGNEE Novo Nordisk A/S

(B) RESIDENCE: (CITY & STATE OR COUNTRY) Bagsvaerd, Denmark

Please check the appropriate assignee category indicated below (will not be printed on the patent)

☐ Individual ☒ corporation or other private group entity ☐ government

4a. The following fees are enclosed (make check payable to Commissioner of Patents and Trademarks):

☐ Issue Fee
☐ Advance Order - # of Copies _____

4b. The following fees or deficiency in these fees should be charged to:

DEPOSIT ACCOUNT NUMBER 14-1447
 (ENCLOSE AN EXTRA COPY OF THIS FORM)

☒ Issue Fee
☒ Advance Order - # of Copies (2) two

The COMMISSIONER OF PATENTS AND TRADEMARKS IS requested to apply the Issue Fee to the application identified above.

(Authorized Signature)

(Date)
10/31/00

NOTE: The Issue Fee will not be accepted from anyone other than the applicant, a registered attorney or agent, or the assignee or other party in interest as shown by the records of the Patent and Trademark Office.

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending on the needs of the individual case. Any comments on the amount of time required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND FEES AND THIS FORM TO: Box Issue Fee, Assistant Commissioner for Patents, Washington D.C. 20231

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMIT THIS FORM WITH FEE

Attorney Docket No.: 3469,224-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Rasmussen et al.

Confirmation No: 5039

Serial No.: 09/189,028

Group Art Unit: 1652

Filed: November 10, 1998

Examiner: L. Hobbs

For: A Cellulase Preparation Comprising An Endoglucanase Enzyme

CERTIFICATE OF FACSIMILE TRANSMISSION

Commissioner for Patents
Washington, DC 20231

Sir:


I hereby certify that the attached correspondence comprising:

1. Amendment
3. Abstract

was sent to the United States Patent and Trademark Office by telefax to the attention of Examiner L. Hobbs, fax number (703) 746-5220.

Respectfully submitted,

Date: December 17, 2001


Kelley O'Patry
Novozymes North America, Inc.
405 Lexington Avenue, Suite 6400
New York, NY 10174-6401
(212) 867-0123

10/8
Rule 312

OK to enter